Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Junya Zhu"'
Autor:
Nebras Abu Al Hamayel, Susan M. Hannum, Sydney M. Dy, Junya Zhu, Sarina R Isenberg, Anne Walling, Ritu Sharma, Kamini Kuchinad, Arif H. Kamal, Karl A. Lorenz, Zi Rou Liew
Publikováno v:
Journal of Oncology Practice. 14:e834-e843
Purpose: To evaluate the reliability, content validity, and variation among sites of a survey to assess facilitators and barriers to quality measurement and improvement in palliative care programs. Methods: We surveyed a sample of diverse US and Cana
Autor:
Junya Zhu, Chengqi Guan, Yuejiao Huang, Yanhua Liu, Bo-Jun Bao, Lili Ji, Jianguo Zhang, Runzhou Ni, Xiaojing Yang, Lei Yang
Publikováno v:
Tumor Biology. 37:4115-4126
The human far upstream element (FUSE) binding protein 1 (FUBP1) belongs to an ancient family which is required for proper regulation of the c-Myc proto-oncogene. Although c-Myc plays an important role in development of various carcinomas, the relevan
Autor:
Mei Li, Junya Zhu, Wenjuan Chen, Huiyuan Qiu, Jinxia Liu, Weijian Guo, Runzhou Ni, Jianguo Zhang, Huijie Wang, Shu Zhang, Sujie Ni
Publikováno v:
Tumor Biology. 36:747-756
NF45 (also known as ILF2), as one subunit of NF-AT (nuclear factor of activated T cells), repairs DNA breaks, inhibits viral replication, and also functions as a negative regulator in the microRNA processing pathway in combination with NF90. Recently
Publikováno v:
Cancer. 119:2048-2060
BACKGROUND Randomized trials report equivalent efficacy among various combinations of platinum-based regimens in advanced non–small cell lung cancer (NSCLC). Their relative effectiveness and comparability based on squamous versus nonsquamous histol
Autor:
Angela Cleary, Junya Zhu, Douglas Brandoff, Kristen G. Schaefer, Jane C. Weeks, Maureen P. Lynch, Sherri O. Stuver, Saul N. Weingart, Susan D. Block, Donna L. Berry
Publikováno v:
Journal of Pain and Symptom Management. 43:1072-1081
Context Pain is common among patients with advanced cancer despite the dissemination of clinical pain care guidelines. Objectives We sought to assess the quality of pain care among patients with advanced disease. Methods We reviewed the records of 85
Autor:
Saul N. Weingart, Terry Kahlert Eng, Justin Spencer, Janet Korman-Parra, Brett Simchowitz, Laurinda Morway, Kathleen Horvath, Junya Zhu, Christine Cleary
Publikováno v:
The Joint Commission Journal on Quality and Patient Safety. 35:63-71
Article-at-a-Glance Background Health care organizations have begun to adapt high-performance teamwork training techniques from aviation to clinical environments. Oncology care is often delivered in multispecialty teams and with the patient's and fam
Autor:
Junya Zhu, Bin Ji, Wenjuan Chen, Na Ban, Jie Sun, Yuchan Wang, Donglin Wang, Li Zhang, Shaochen Fan, Yan Wang
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(3)
Cell division cycle 5-like (CDC5L) protein is a cell cycle regulator of the G2/M transition and has been reported to participate in the catalytic step of pre-messenger RNA (mRNA) splicing and DNA damage repair. Recently, it was also found to act as a
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 36(9)
CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells. CtBP2 was also demonstrated to contribute to the proliferation of es
Autor:
Lili Ji, Chengqi Guan, Runzhou Ni, Lei Yang, Li Liang, Junya Zhu, Yayun Wang, Jianguo Zhang, Jia Zhu
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(10)
SYF2, also known as CCNDBP1-interactor or p29, is reported in pre-mRNA splicing and cell cycle progression. However, the role of SYF2 in esophageal squamous cell carcinoma (ESCC) development remains elusive. In the present study, Western blot and imm
Publikováno v:
JAMA. 307(15)
Context A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non–small cell lung cancer (NSCLC). However, longer survival was not observed in the subgroup of patients aged 65 y